A three or more drug combination as effective therapy for moderate or severe chronic graft-versus-host disease

Area of Science:

• Hematology
• Immunology
• Pediatric Hematology

Background:

• Allogeneic stem cell transplantation (SCT) is a curative option for thalassemia.
• Chronic graft-versus-host disease (cGVHD) is a significant complication post-SCT.
• Effective management of cGVHD is crucial for improving outcomes.

Purpose of the Study:

• To evaluate the efficacy and safety of multi-drug regimens for moderate to severe cGVHD in pediatric thalassemia patients.
• To compare outcomes based on the number of drugs used and treatment line (first-line vs. salvage).

Main Methods:

• Retrospective analysis of 45 thalassemia patients with moderate to severe cGVHD.
• Patients received either a three-drug regimen (cyclosporine, methylprednisolone, azathioprine) or a four/five-drug regimen (including cyclophosphamide and/or methotrexate).
• Treatment was categorized as first-line or salvage therapy.

Main Results:

• Overall complete response (CR) rate was 77.3%.
• First-line three-drug therapy achieved 94% CR, with an 89% probability of CR and 89% survival.
• Salvage three-drug therapy yielded 88% CR, while four/five-drug regimens showed lower CR rates (36.6%) and survival probabilities.
• Treatment-related complications and mortality (20%, mainly infectious) were lower with first-line three-drug therapy.

Conclusions:

• Multi-drug combination therapy is safe and effective for moderate to severe cGVHD in young thalassemia patients.
• A three-drug regimen, especially as first-line therapy, offers superior response and survival rates with fewer complications.
• Infectious complications remain a significant cause of treatment-related mortality.